EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

  • Jacques Darcourt
  • Jan Booij
  • Klaus Tatsch
  • Andrea Varrone
  • Thierry Vander Borght
  • Özlem L. Kapucu
  • Kjell Någren
  • Flavio Nobili
  • Zuzana Walker
  • Koen Van Laere


These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the “Kompetenznetz-Parkinson” sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.


Brain DAT SPECT Parkinson 


  1. 1.
    Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29(10):BP30–5.PubMedGoogle Scholar
  2. 2.
    Bartenstein P, Grunwald F, Kuwert T, Tatsch K, Sabri O, Benkert O, et al. Clinical applications of single photon emission tomography in neuromedicine. 1. Neuro-oncology, epilepsy, movement disorders, cerebrovascular disease. Nuklearmedizin 2000;39(7):180–95.PubMedGoogle Scholar
  3. 3.
    Payoux P, Baulieu JL, Darcourt J, Guedj E, Habert MO, Prunier C, et al. Guide pour la rédaction de protocoles pour la scintigraphie à l’aide de ligands des transporteurs présynaptiques de la dopamine dans le striatum. Médecine Nucléaire 2008;32:623–5.CrossRefGoogle Scholar
  4. 4.
    Catafau AM. Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact. Nucl Med Commun 2001;22(10):1059–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands – state of the art and new trends. Q J Nucl Med 2001;45(2):139–52.PubMedGoogle Scholar
  6. 6.
    Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001;22(7):819–27.CrossRefPubMedGoogle Scholar
  7. 7.
    DaTSCAN European Public Assessment Report. 072200en6.pdf and DaTSCAN-H-266-AR-II.pdf, http://www.emea.europa.eu/humandocs/Humans/EPAR/datscan/Datscan.htm.
  8. 8.
    Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15(3):503–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40(5):753–61.PubMedGoogle Scholar
  10. 10.
    Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22(9):1229–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27.CrossRefPubMedGoogle Scholar
  12. 12.
    McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6(4):305–13.CrossRefPubMedGoogle Scholar
  13. 13.
    O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61(6):919–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78(11):1176–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62(2):133–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996;46(1):231–7.PubMedGoogle Scholar
  17. 17.
    Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15(4):692–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001;57(11):2089–94.PubMedGoogle Scholar
  19. 19.
    Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35(2):424–38.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, et al. Decreased dopamine transporter availability in male smokers-a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):274–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2005;32(12):1452.CrossRefPubMedGoogle Scholar
  22. 22.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351(24):2498–508.CrossRefPubMedGoogle Scholar
  23. 23.
    Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [(123)I]FP-CIT. Eur J Nucl Med Mol Imaging 2008;35(7):1343–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Dobbeleir AA, Hambÿe A-SE, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low-and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med Mol Imaging 1999;26(6):655.CrossRefGoogle Scholar
  25. 25.
    Koch W, Hamann C, Welsch J, Popperl G, Radau PE, Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? J Nucl Med 2005;46(11):1804–11.PubMedGoogle Scholar
  26. 26.
    Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med 2003;44(7):1184–93.PubMedGoogle Scholar
  27. 27.
    Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999;40(7):1091–7.PubMedGoogle Scholar
  28. 28.
    Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 2007;34(8):1240–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Kas A, Payoux P, Habert M-O, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 2007;48(9):1459–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46(7):1109–18.PubMedGoogle Scholar
  31. 31.
    Booij J, Busemann Sokole E, Stabin MG, Janssen AG, de Bruin K, van Royen EA. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998;25(1):24–30.CrossRefPubMedGoogle Scholar
  32. 32.
    Kuikka JT, Bergstrom KA, Ahonen A, Lansimies E. The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane. Eur J Nucl Med 1994;21(1):53–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med 1994;35(5):764–70.PubMedGoogle Scholar

Copyright information

© EANM 2009

Authors and Affiliations

  • Jacques Darcourt
    • 1
    • 11
  • Jan Booij
    • 2
  • Klaus Tatsch
    • 3
  • Andrea Varrone
    • 4
  • Thierry Vander Borght
    • 5
  • Özlem L. Kapucu
    • 6
  • Kjell Någren
    • 7
  • Flavio Nobili
    • 8
  • Zuzana Walker
    • 9
  • Koen Van Laere
    • 10
  1. 1.Nuclear Medicine, Centre Antoine Lacassagne and University HospitalUniversité de Nice Sophia AntipolisNiceFrance
  2. 2.Department of Nuclear MedicineAcademic Medical Center AMCAmsterdamThe Netherlands
  3. 3.Department of Nuclear MedicineMunicipal Hospital of Karlsruhe IncKarlsruheGermany
  4. 4.Department of Clinical Neuroscience Psychiatry SectionKarolinska InstituteStockholmSweden
  5. 5.Nuclear Medicine DivisionUniversité Catholique de Louvain Medical Center, Mont-Godinne Medical CenterLouvain-la-NeuveBelgium
  6. 6.Department of Nuclear Medicine, Faculty of MedicineGazi UniversityAnkaraTurkey
  7. 7.Department of Clinical Physiology and Nuclear Medicine, RigshospitaletUniversity of Copenhagen University HospitalCopenhagenDenmark
  8. 8.Clinical Neurophysiology Unit, San Martino HospitalUniversity of GenovaGenovaItaly
  9. 9.Psychiatry, Department of Mental Health SciencesUniversity College LondonLondonUK
  10. 10.Division of Nuclear MedicineUniversity Hospital LeuvenLeuvenBelgium
  11. 11.Faculté de MédecineUniversité de NiceNice cedex 02France

Personalised recommendations